Transporter-mediated drug interactions: clinical implications and in vitro assessment.

@article{Lin2007TransportermediatedDI,
  title={Transporter-mediated drug interactions: clinical implications and in vitro assessment.},
  author={Jiunn Huei Lin},
  journal={Expert opinion on drug metabolism & toxicology},
  year={2007},
  volume={3 1},
  pages={
          81-92
        }
}
  • Jiunn Huei Lin
  • Published in
    Expert opinion on drug…
    2007
  • Medicine
  • Although they are less frequently compared with the reported cases of CYP-mediated drug interactions, clinically significant transporter-mediated drug interactions, which are mainly based on efflux transporter or P-glycoprotein data, have been reported. Unlike the CYP-mediated drug interactions that can be readily defined by inhibition or induction of CYP enzymes, the evidence for the so-called transporter-mediated drug interactions is often less conclusive. The difficulty in defining… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 33 CITATIONS

    Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.

    VIEW 7 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.

    Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.

    VIEW 2 EXCERPTS
    CITES BACKGROUND